Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine for the Prevention of COPD Exacerbations (ENHANCE-3)
NCT07874815Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Apr 2029
01
Overview
A Phase 3 trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Merck & Co.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07874815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874815.